DCLK1-IN-1

Target: DCLK1-IN-1 targets the kinase domains of DCLK1 and DCLK2 in biochemical assays.

Mechanism of Action: DCLK1-IN-1 provides a kinase-domain recognition element for designing DCLK1/2-directed degraders. In a PROTAC, the DCLK1-IN-1-derived portion binds DCLK1 or DCLK2, and a linker presents this bound protein to an E3 ligase ligand. The linker length, exit vector, and E3 recruiter must be optimized to favor cooperative ternary-complex formation rather than simple binary binding. A productive complex enables the E3 ligase to transfer ubiquitin to accessible lysines on DCLK1/2, leading to proteasome-dependent depletion of the targeted kinase protein. This establishes a testable protein-depletion mechanism for research assays.

• DCLK1-Directed PROTAC Design: DCLK1-IN-1 can serve as a DCLK1-binding ligand to construct PROTACs aimed at selectively recruiting an E3 ligase and triggering DCLK1 ubiquitination. This enables systematic evaluation of how linker length, attachment position, and E3 ligase choice influence DCLK1 degradation efficiency and degradation kinetics in relevant cellular models.

• Optimizing Degradation Potency: Use DCLK1-IN-1 as the targeting module in PROTAC libraries to optimize degradation potency rather than occupancy alone. By varying PROTAC architecture, researchers can probe structure–activity relationships that govern ternary complex formation, residence time, and the transition from ubiquitination to proteasomal processing of DCLK1.

• Pathway and Phenotype Mapping: DCLK1-IN-1-based PROTACs can be applied to dissect DCLK1-driven signaling outputs by comparing degradation versus inhibitor-only controls. This supports mechanistic studies linking DCLK1 removal to downstream transcriptional programs, cell-state changes, and stress-response pathways, clarifying whether phenotypes correlate with degradation extent.

• Selectivity and Off-Target Profiling: Incorporate DCLK1-IN-1 into PROTACs to assess target selectivity across related kinases and neuronal differentiation regulators. Proteome-wide or targeted immunoblot panels can determine whether degradation is specific to DCLK1, helping refine ligand choice and PROTAC design to minimize off-target ubiquitination and unintended protein loss.

• Resistance Mechanism Studies: DCLK1-IN-1 PROTACs can be used to investigate resistance mechanisms that limit targeted degradation. Researchers can test how alterations in E3 ligase expression, proteasome function, or DCLK1 pathway feedback affect degradation durability, guiding iterative PROTAC redesign to restore robust DCLK1 turnover under challenging cellular conditions.

DCLK1-IN-1 is a DCLK1/DCLK2-directed chemical probe with a high-affinity kinase-binding scaffold suitable for mechanistic degrader exploration. Its benzodiazepinone-fused heteroaromatic core and piperazine substituent provide a recognizable target-ligand framework for PROTAC exit-vector studies. This molecule is described in detail below.

Structure: The molecule features a pyrimido-benzodiazepinone core bearing an anilino linkage, methoxy substituent, trifluoroethyl group, and N-methylpiperazine. This architecture combines rigid kinase-binding heteroaromatics with a basic solubilizing side chain that may be useful for derivatization studies.

Reactivity: For DCLK1 degrader design, the N-methylpiperazine/anilino aryl region is the most logical area to examine for linker elaboration, but any exit vector must be validated against DCLK1 and DCLK2 binding because the fused core likely contributes essential hinge and pocket contacts. PEG, alkyl, or piperazine-compatible amide/urea linkers may be paired with CRBN or VHL ligase ligands, with E3-ligase selection guided by cellular expression and degradation readouts.